Intuitive Surgical Is Slipping Soon after Earnings. This Analyst Thinks It really is a Buy.
Textual content dimensions
robotic surgical equiptment
Dreamstime
Shares of
Intuitive Surgical
have been falling Friday soon after the surgical equipment manufacturer reported earnings. But a Citigroup analyst believes the pullback is a obtaining chance.
Intuitive Surgical (ticker:
ISRG
) noted an adjusted fourth-quarter revenue of $1.30 a share, beating forecasts for $1.28 a share, on gross sales of $1.55 billion, which topped anticipations for $1.52 billion.
Irrespective of the stable efficiency, buyers reacted to close to-phrase headwinds on Friday, with the inventory dropping 8.3% to $268.30.
Covid-19 appreciably disrupted surgical techniques in the fourth quarter of 2021, the company reported. Executives assume the pandemic to proceed to adversely effect the quantity of methods for the rest of the yr.
Administration also foresees 2022 currently being a large 12 months for around-time period financial investment. That disclosure all through Thursday’s earnings get in touch with with buyers was weighing on the inventory, according to analysts.
For Citigroup analyst Joanne Wuensch, the pullback is an option. Wuensch upgraded the inventory to Buy from Neutral.
“While we imagine macro headwinds and the biking out of ‘growth’ stocks may possibly weigh on ISRG in the near-term, heritage has revealed the best time to invest in MedTech shares is when they have retraced and/or disappointed,” she wrote.
Wuensch also diminished her cost focus on to $360 from $370, indicating that Intuitive’s valuation has contracted around the limited expression. The analyst minimize her income and earnings estimates for 2022, 2023, and 2024, as Covid will carry on to delay treatments, positioning strain on source chains and labor.
Other analysts continued to be bullish on the stock’s extensive-term performance. Raymond James analyst Jayson Bedford taken care of his Outperform rating, citing Intuitive’s management place in surgical robotics. Bedford reduced his value concentrate on to $334, down from $383, citing reduce earnings estimates and significantly less of an trader appetite for progress shares as the Federal Reserve is predicted to shortly commence mountaineering curiosity costs.
J.P. Morgan also taken care of an Chubby rating on the stock, and retained the selling price goal at $370.
“Looking forward, we think the 2022 method assistance is conservative, with place for upside irrespective of lingering Covid impacts,” they wrote in a exploration be aware.
The analysts see several catalysts that can drive that upside in the very long operate, which include increasing in un-penetrated processes, perhaps launching a new da Vinci method, and a rollout of versatile funding courses.
Write to Sabrina Escobar at [email protected]